Fast track tag granted to BioSight's BST-236 for AML
BioSight's investigational drug BST-236, or aspacytarabine, gained the FDA's Fast Track designation as a treatment for adults with acute myeloid leukemia aged 75 years or older or for those unable to undergo induction chemotherapy. The agent is a novel antimetabolite being tested in a Phase IIb trial, and another midstage trial for BST-236 will be launched later this year to test the drug in patients with relapsed/refractory AML, or myelodysplastic syndrome. Healio (free registration) (8/4)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!